Provided by Tiger Fintech (Singapore) Pte. Ltd.

IceCure Medical Ltd.

1.42
+0.04002.90%
Post-market: 1.41-0.0108-0.76%17:09 EDT
Volume:165.89K
Turnover:233.53K
Market Cap:80.33M
PE:-4.96
High:1.45
Open:1.39
Low:1.38
Close:1.38
Loading ...

IceCure Medical’s Cryoablation Shows Higher Patient Satisfaction in Japan Study

TIPRANKS
·
10 Mar

Breast Cancer Patients who Underwent IceCure's ProSense® Cryoablation in Japan Reported Significantly Higher Satisfaction than Patients who Underwent Standard of Care Surgery

PR Newswire
·
10 Mar

IceCure Medical files for regulatory approval of cryoablation system in Israel

TIPRANKS
·
24 Feb

Icecure Submits Filing for Regulatory Approval of Its Next-Generation Xsense™ Cryoablation System in Israel

THOMSON REUTERS
·
24 Feb

IceCure Submits Filing for Regulatory Approval of its Next-Generation XSense™ Cryoablation System in Israel

PR Newswire
·
24 Feb

IceCure Medical Ltd's (NASDAQ:ICCM) Profit Outlook

Simply Wall St.
·
18 Feb

IceCure Medical Awaits FDA Decision as ProSense® Gains Attention

TIPRANKS
·
04 Feb

IceCure's ProSense® in the Spotlight at Society of Interventional Oncology (SIO) Annual Meeting: Award Winning Abstract and Hands-On Training for Breast Cryoablation as Medical Community Anticipates FDA's Market Authorization Decision

PR Newswire
·
04 Feb

IceCure Medical Seeks to Expand in China with ProSense® Cryoablation System

TIPRANKS
·
27 Jan

Icecure Files for Regulatory Approval of Prosense® Cryoablation System in China

THOMSON REUTERS
·
27 Jan

IceCure Files for Regulatory Approval of ProSense® Cryoablation System in China

PR Newswire
·
27 Jan

Icecure Medical : Entered Into Equity Distribution Agreement With Maxim Group Llc

THOMSON REUTERS
·
13 Jan

Icecure Medical Ltd: May Offer, Sell Ordinary Shares of up to $13.96 Mln From Time to Time

THOMSON REUTERS
·
13 Jan

IceCure Medical Reports Strong Growth and Anticipates FDA Approval in 2025

TIPRANKS
·
13 Jan

IceCure Medical CEO Issues Letter to Shareholders & Reports Increase of 42% in ProSense® Sales for 2024 in North America

PR Newswire
·
13 Jan

The five-year returns have been enviable for IceCure Medical (NASDAQ:ICCM) shareholders despite underlying losses increasing

Simply Wall St.
·
08 Jan